Travere Therapeutics, Inc. (TVTX) Stock

Travere Therapeutics, Inc. (TVTX) is a Healthcare stock trading at $65.70 (as of 2026-08-21), with a market capitalization of $6.11B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Travere Therapeutics, Inc. is a biopharmaceutical company focused on finding, developing, and commercializing therapies for rare diseases. Its marketed treatments include Chenodal, Cholbam, and Thiola/Thiola EC, and its pipeline includes clinical-stage candidates such as Sparsentan and TVT-058 for conditions including kidney and metabolic disorders.

Understand Travere Therapeutics, Inc.: how it makes money

Travere Therapeutics develops and sells therapies for rare diseases, including marketed drugs such as Chenodal and Cholbam, and it makes money from net product sales and from collaboration related items such as milestones, license revenue, and other collaboration arrangements.

The profit model hinges on whether recurring net product sales, especially from Filspari, can outweigh operating losses, while also recognizing that some revenue in the quarter comes from milestone and other collaboration items that can be timing dependent.

Revenue by segment (latest quarter)
Filspari$0.0B
CSL Vifor milestones$0.1B
Rinalis option$0.0B
Renalys license$0.0B

Business quality (Weak): Useful snapshot of a single quarter, but the available segment inputs appear to be selected revenue line items rather than a clearly disclosed full set of official reportable segments, and several collaboration categories show 0.0 in this period.

Bull case

  • Product revenue is a defined driver: Filspari net product sales are a key component of the quarter's revenue mix, making it a central operational metric to track.
  • Collaboration can add revenue in specific periods: The quarter includes market access milestone revenue and milestone payment revenue related to CSL Vifor, which can supplement product sales.

Bear case

  • Operating losses remain large: The latest period shows an operating margin of -29.0%, indicating costs exceed operating revenue.
  • Revenue can be volatile due to collaboration and non-cash items: Some reported revenue categories in the provided data include milestone revenue and non-cash license or relinquishment items, which may not repeat in future quarters.
  • Some collaboration revenue categories are zero in the quarter: The provided data shows license and collaboration revenue at 0.0 for this period, which suggests near-term contribution from those categories may be limited.
Valuation — source: SEC EDGAR (first-party)
Price$65.70
Market Cap$6.11B
EV / EBITDA261.5
Price / Book249.15
Price / Sales10.33
FCF Yield0.2%
DCF Value (model)$2.73
DCF Upside vs Price-95.8%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$490.73M
Net Margin-5.2%
Revenue Growth (YoY)48.2%
EPS Growth (YoY)164.3%
Financial Health — source: SEC EDGAR
Altman Z-Score5.03 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderJupiter Topco LLC ($643.30M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOEric Dube
Employees385
CountryUS
IPO Date2012-11-08

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

  • Nature's Sunshine Products, Inc. (NATR)
  • Mirum Pharmaceuticals, Inc. (MIRM)
  • Organogenesis Holdings Inc. (ORGO)
  • Innoviva, Inc. (INVA)
  • Catalyst Pharmaceuticals, Inc. (CPRX)
  • Ardelyx, Inc. (ARDX)
  • Esperion Therapeutics, Inc. (ESPR)
  • Insmed Incorporated (INSM)
TVTX earnings history · TVTX institutional & insider holders · TVTX KPIs & operating metrics · TVTX financials · TVTX investor presentations & press releases · TVTX SEC filings · TVTX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.